Alberta Investment Management Corp Acquires New Stake in Emergent Biosolutions Inc. (NYSE:EBS)

Key Points

• Alberta Investment Management Corp made a new investment of approximately $458,000 in Emergent Biosolutions Inc., acquiring 94,200 shares during the first quarter.
• Emergent Biosolutions' shares saw a 6.0% increase in value, with the stock price opening at $5.97 and a market capitalization of $323.78 million.
• Institutional investors own 78.40% of Emergent Biosolutions, indicating significant interest from large funds, including recent substantial stake increases from Covestor Ltd and SBI Securities Co. Ltd.

Alberta Investment Management Corp purchased a new stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 94,200 shares of the biopharmaceutical company's stock, valued at approximately $458,000. Alberta Investment Management Corp owned 0.17% of Emergent Biosolutions as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in EBS. Covestor Ltd increased its stake in shares of Emergent Biosolutions by 5,458.5% during the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 2,893 shares during the last quarter. SBI Securities Co. Ltd. increased its position in shares of Emergent Biosolutions by 95.1% during the first quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 6,313 shares during the period. Corton Capital Inc. bought a new position in shares of Emergent Biosolutions during the 1st quarter worth about $70,000. Bank of New York Mellon Corp boosted its holdings in Emergent Biosolutions by 40.4% during the first quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 4,894 shares in the last quarter. Finally, EP Wealth Advisors LLC bought a new position in shares of Emergent Biosolutions during the fourth quarter valued at $110,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Emergent Biosolutions

In other news, Director Keith Katkin sold 7,844 shares of the business's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $6.30, for a total value of $49,417.20. Following the completion of the sale, the director owned 86,431 shares of the company's stock, valued at approximately $544,515.30. The trade was a 8.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Emergent Biosolutions Trading Up 6.5%

NYSE EBS traded up $0.54 during trading hours on Friday, hitting $8.78. The company's stock had a trading volume of 2,044,504 shares, compared to its average volume of 1,250,284. The stock has a fifty day moving average of $6.68 and a 200 day moving average of $6.69. The company has a quick ratio of 3.51, a current ratio of 6.32 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $476.29 million, a P/E ratio of 3.59 and a beta of 1.97. Emergent Biosolutions Inc. has a twelve month low of $4.02 and a twelve month high of $13.28.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.42. The business had revenue of $140.90 million for the quarter, compared to analyst estimates of $148.55 million. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.89%. Equities research analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.